SavedAdd your journal

Journals / Eurasian Journal of Emergency Medicine / 2019 / Cilt: 18 - Sayı: 2

An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure

Ekim SAĞLAM GÜRMEN
Adnan BİLGE
Pages
119–121
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to present and discuss an unusual side effect of dabigatranetexilate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Dabigatran etexilate is a prodrug with anticoagulant effect through inhibition of thrombin.
📊
Key Findings & Data:Although it does not require laboratorymonitoring and has minimal food-drug interaction, its disadvantages are bleeding, common GIS-related side effects and the need fordosage adjustment according to the severity of liver/renal failure.
💡
Conclusion & Impact:We aimed to present and discuss an unusual side effect of dabigatranetexilate.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Dabigatran etexilate is a prodrug with anticoagulant effect through inhibition of thrombin. Although it does not require laboratorymonitoring and has minimal food-drug interaction, its disadvantages are bleeding, common GIS-related side effects and the need fordosage adjustment according to the severity of liver/renal failure. We aimed to present and discuss an unusual side effect of dabigatranetexilate.

🔖

Cite This Article

GÜRMEN, E. S., BİLGE, A. (2022). An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure. Eurasian Journal of Emergency Medicine, Cilt: 18 - Sayı: 2, 119–121. https://ajindex.com/articles/507997

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372-80
  2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51
  3. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-47
  4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92
  5. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association pratical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-51
  6. Liew A, Eikelboom JW, O’Donnell M, Hart RG. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol. 2013;29(7 Suppl):34-44
  7. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran reversal. N Engl J Med. 2015;373:511-20
  8. PRADAXAR 75 mg sertkapsul. Boehringer Ingelheim İlacTicaret A.Ş. RuhsatTarihi: 14.03 2011 KUB Tarihi: 13.05.2011 Available from:http: //www. iegm.gov.tr/Folders/KubKT/
  9. Kaiser C. Pradaxa Benefit Outweighs Bleeding Risk, FDA Says. Dec 7, 2011; Available from: http: //abcnews.go.com/Health/ HeartDiseaseNews/pradaxabenefit- outweighs bleedingriskfda/story?id=15106519#.TuUOJdXiVHQ.